Key Takeaways
Aggression is not a diagnostic feature of psychiatric disorders but is often linked to mental illness and emergency presentations.
The dopamine D4 receptor, particularly its polymorphisms, is associated with aggression, suggesting a potential target for treatment.
Clozapine is the most effective antiaggression agent, outperforming risperidone, olanzapine, and haloperidol in studies.
Asenapine and loxapine also demonstrate efficacy in reducing aggression, independent of their antipsychotic effects.
Targeting aggression directly, rather than solely treating the underlying disorder, may improve treatment outcomes for patients.
CLINICAL REFLECTIONS
Violence and aggression are not diagnostic features of any psychiatric disorder. Nonetheless, many individuals associate these symptoms with mental illness, and they are often the precipitant for emergency presentations and hospitalization. Additionally, society associates severe mental illness with both aggression and violence, a belief that is reinforced by media, politicians, and others. Yet, excluding substance use, the rates of aggression and violence by patients with psychiatric disorders are similar to those occurring in the general population.
Despite the fact that aggression has not been identified as a symptom of any specific psychiatric disorder, it is still seen as a consequence of associated disorders. Treatment of aggression is currently constrained within treatment of the associated disorder. However, there are sufficient data to suggest that it is reasonable to view aggression itself as a potential target for treatment.
Pathophysiology of Aggression
Several studies have attempted to discern the physiologic congenators of aggression. Although there are many findings, most are probably associations rather than causative. The most reproducible and important of these studies have been associations of polymorphisms of the dopamine D4 receptor with aggression. DRD4 is the gene that codes for the dopamine D4 receptor. It is found on the short arm of the 11th chromosome. Stimulation of D4 activates the inhibitory G protein second messenger system (Gai) and inhibits cyclic adenosine monophosphate formation. D4 is expressed in the frontal cortex, where it is much more common than the D2 receptor, as well as in the thalamus, hypothalamus, and olfactory bulb. The DRD4 gene has a polymorphic third exon. This part of the gene codes for the third cytoplasmic loop of the protein, which interacts with the Gai second messenger. The polymorphism presents as a variable number of repeats within this 48–base pair section. In the population, the number of repeats varies between 2 and 11 times.
A common variant is the 7-repeat allele, which is best known for its association with attention-deficit/hyperactivity disorder. But it has also been associated with novelty seeking, impulsivity, anger, and aggression. This association gains importance when one becomes aware that D4 antagonists with high affinity that exceeds affinity for D2 by the same drug have significant antiaggression properties. The Table summarizes the affinities, expressed as dissociation constants (Ki), of several antipsychotics. In general, while second-generation antipsychotics have been described to have greater affinity for D4 than D2, that is generally not true.
Antiaggression Agents
The most effective antiaggression agent available is clozapine. This has been repeatedly demonstrated in open studies as well as in randomized trials. In the blinded, randomized studies, clozapine was superior to risperidone, olanzapine, and haloperidol. Specifically, the likelihood for aggressive behaviors after study entry was significantly lower for clozapine (17.5%) vs olanzapine (23.1%), risperidone 24.4%, and haloperidol (45.9%). Measured aggression was significantly less likely to happen with clozapine than haloperidol (physical aggression: OR, 2.04; P < .001; aggression against property: OR, 1.85; P < .001; and verbal aggression: OR, 1.35; P < .001) and olanzapine (physical aggression: OR, 1.33; P < .001; and verbal aggression: OR, 1.32; P < .001, but not aggression against property: OR, 1.10; P = .78). (Risperidone was not examined in this study). In this same study, olanzapine was also superior to haloperidol (physical aggression: OR, 1.54; P < .001; aggression against property: OR, 1.67; P < .001, but not verbal aggression: OR, 1.03; P = .57). In a comparative study that examined the hostility items of the Positive and Negative Syndrome Scale, clozapine was the only agent that significantly reduced measured hostility vs baseline (P = .019) and was superior to risperidone (P = .012) and haloperidol (P = .021) but not olanzapine. More importantly, this effect occurred at therapeutic dosage and was independent of clozapine’s antipsychotic effect or the occurrence of sedation. Clozapine is also effective in a genetic animal model of a developmental disorder (immediate early gene transcription factor, Egr3, knockout) in which the animals become aggressive.
Similarly, asenapine has also demonstrated antiaggression effects in a prospective study comparing asenapine with treatment as usual (TAU) for 48 patients who were admitted with significant aggression. Asenapine was superior to TAU as measured by the Modified Overt Aggression Scale (MOAS). There was a significant reduction in physical aggression (–8.0 ±5.06 vs –0.78 ± 2.40; P < .0001) and total aggression (–14.7 ± 11.59 vs –5.4 ± 10.12; P = .045) as measured by the MOAS. More recently, a post hoc analysis of hostility in 442 patients with schizophrenia treated with a transdermal formulation of asenapine found that hostility improved independent of antipsychotic effect and after correcting for covariates, indicating that the antihostility effect is independent of the antipsychotic effect. Sublingual asenapine has also demonstrated significant reductions in hostility, irritability, and disruptive behavior vs placebo in participants experiencing acute mania. Asenapine may be effective quickly, and in a randomized, placebo-controlled study of agitation in a mixed diagnosis sample (schizophrenia, bipolar disorder, major depressive disorder, anxiety, and posttraumatic stress disorder) it significantly reduced the Excited Component of the Positive and Negative Syndrome Scale. Adequate D4 blockade and the antiaggression effect is likely achieved at 5 mg daily, whereas the minimum antipsychotic dose is 10 mg daily, and it is believed that aggression should improve at 5 mg.
Loxapine is a second-generation antipsychotic agent that was not identified as such prior to the introduction of clozapine. It has a long history of treating aggression, hostility, and agitation in patients with bipolar disorder and schizophrenia experiencing acute mania and psychosis with both injectable and inhalable formulations. Significantly, the effect on reducing aggression in agitated patients appears to occur independent of diagnosis. Receptor occupancy is generally poorly studied in older medications, but the antipsychotic effect (ie, D2 receptor occupancy of 60% to 80%) probably occurs at 15 to 30 mg daily, and since the affinity at D4 is 3 times greater than at D2, one would expect that doses as low as 10 mg daily may be effective for aggression control.
Olanzapine and risperidone also have D4 affinities that exceed D2 affinities. The difference is small but similar to that in asenapine. For all 3 agents, it is likely that both receptors are blocked at doses that are frequently used. All these agents are frequently used in treating aggression because the drugs are approved for use in a wide range of psychiatric disorders. While asenapine has not been compared with clozapine, clozapine appears to be superior to both olanzapine and risperidone. Furthermore, reduction in aggression with olanzapine and risperidone appears to be related to their antipsychotic effect, which does not appear to be the case for clozapine.
Some of these agents have affinity to D4 that exceeds the affinity for D2 (ie, affinity D4 to affinity D2 > 1).5 Clozapine clearly has the best data and is likely superior to other agents. It is superior to risperidone, olanzapine, and haloperidol. It would appear that when a patient presents with aggression as an important symptom, targeting that symptom may have a greater impact than treating the underlying disease.
Note: This article originally appeared on Psychiatric Times.
Comentarios